Current Liabilities

Derivative Liabilities - Fair Value

Biogen Derivative Liabilities - Fair Value decreased by 32.6% to $38.20M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ4 2018
Last reportedQ1 2026

How to read this metric

An increase in liabilities suggests unfavorable market movements for the company's hedges, while a decrease indicates a reduction in potential settlement obligations.

Detailed definition

This represents the fair value of derivative financial instruments that are currently in a liability position. These lia...

Peer comparison

Standard for energy companies; peers with similar hedging profiles will show comparable volatility in this line item.

Metric ID: derivative_liabilities_fair_value

Historical Data

2 periods
 Q4 '25Q1 '26
Value$56.70M$38.20M
QoQ Change—-32.6%
Range$38.20M – $56.70M

Derivative Liabilities - Fair Value at Other Companies

Amgen logo
AmgenAMGNView metric
Roivant Sciences logo
Roivant SciencesROIVView metric
Viatris logo
ViatrisVTRSView metric
Gilead Sciences logo
Gilead SciencesGILDView metric
Merck & Co. logo
Merck & Co.MRKView metric

Frequently Asked Questions

What is Biogen's derivative liabilities - fair value?
Biogen (BIIB) reported derivative liabilities - fair value of $38.20M in Q1 2026.
What does derivative liabilities - fair value mean?
The total market value of all derivative contracts that are currently resulting in a loss.